Compare BXC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXC | CTNM |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | 1700 | 51 |
| Industry | Wholesale Distributors | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.2M | 480.5M |
| IPO Year | 2004 | 2024 |
| Metric | BXC | CTNM |
|---|---|---|
| Price | $56.09 | $12.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $86.00 | $19.00 |
| AVG Volume (30 Days) | 93.6K | ★ 315.0K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | $2,801.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.78 | $3.35 |
| 52 Week High | $88.30 | $16.33 |
| Indicator | BXC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 45.42 |
| Support Level | $52.71 | $11.54 |
| Resistance Level | $66.64 | $13.18 |
| Average True Range (ATR) | 2.44 | 0.91 |
| MACD | 1.21 | 0.02 |
| Stochastic Oscillator | 87.21 | 41.38 |
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.